The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Failure to correctly regulate cell death leads to a number of diseases, including cancers and auto-immune diseases. Viruses have the ability to hijack the host cell death machinery for their own benefit. Viral infections have been linked to a number of cancers. We aim to target the ability of viruses to hijack the process of cell death to develop new treatments against virus-linked cancers including Burkitt's Lymphoma and Nasopharyngeal Carcinoma.
Skin cancer affects 60% of Australians. Nicotinamide (vitamin B3) prevents many of sunlight’s damaging effects and reduces premalignant keratoses by 35% compared to placebo in sun-damaged individuals. We now need to test whether nicotinamide can prevent skin cancer. Skin cancer patients will receive nicotinamide or placebo for 12 months and new cancers will be counted in each group. Nicotinamide is safe, widely available and an exciting opportunity for cost-effective skin cancer prevention.
Rob Ramsay has had a long standing research commitment to understanding bowel and breast cancer using mouse models with defined genetic defects. These sophisticated models replicate various stages of cancer development and some have profound effects on normal tissue biology. He also uses molecular tools to investigate how genes are controlled. These approaches are providing direct input into the development of therapeutic agents for cancer treatment.
Cancers of the skin are the most common tumours in humans, and their diagnosis and treatment impose the largest costs on Australia’s cancer budget. While much has been learned about the roles of sunlight and skin type as risk factors for skin cancer, relatively little is known about the genes conferring risk. This study will compare the genetic profiles of over 6000 patients with skin cancer to 3000 people without skin cancer to pinpoint the genes responsible for skin cancer.
Microparticles As Novel Biomarkers In Liver Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,833.00
Summary
No current highly sensitive or specific diagnostic and prognostic biomarker for hepatocellular carcinoma (HCC) exists. We will identify novel nucleic acid signatures in the circulation of patients with HCC through Next Generation Sequencing. Plasma microvesicles will be isolated and their contents analyzed to identify novel genetic biomarkers and fusion gene constructs specific for HCC. Resultant panel of novel biomarkers for HCC will be validated on the Australian STREP cohort of HCC patients.
A Novel Tumour Suppressor Function Of E2F7 In Squamous Cell Carcinoma Formation
Funder
National Health and Medical Research Council
Funding Amount
$524,124.00
Summary
squamous cell carcinomas of the skin are the second most common skin cancer. In this proposal we present data showing that a new gene, E2F7, may play an important role in the development of squamous cell carcinoma. If true, these studies will identify a new therapeutic target that could be exploited in developing novel anticancer therapies.